Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CV Sciences (CVSI) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for CV Sciences (CVSI) over the last 14 years, with Q3 2025 value amounting to $381000.0.

  • CV Sciences' Cash & Equivalents fell 6108.27% to $381000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $381000.0, marking a year-over-year decrease of 6108.27%. This contributed to the annual value of $454000.0 for FY2024, which is 6552.77% down from last year.
  • Latest data reveals that CV Sciences reported Cash & Equivalents of $381000.0 as of Q3 2025, which was down 6108.27% from $886000.0 recorded in Q2 2025.
  • Over the past 5 years, CV Sciences' Cash & Equivalents peaked at $5.2 million during Q1 2021, and registered a low of $381000.0 during Q3 2025.
  • In the last 5 years, CV Sciences' Cash & Equivalents had a median value of $1.0 million in 2022 and averaged $1.4 million.
  • Per our database at Business Quant, CV Sciences' Cash & Equivalents skyrocketed by 11554.83% in 2023 and then plummeted by 7177.51% in 2024.
  • Over the past 5 years, CV Sciences' Cash & Equivalents (Quarter) stood at $1.4 million in 2021, then crashed by 55.56% to $611000.0 in 2022, then skyrocketed by 115.55% to $1.3 million in 2023, then plummeted by 65.53% to $454000.0 in 2024, then dropped by 16.08% to $381000.0 in 2025.
  • Its Cash & Equivalents stands at $381000.0 for Q3 2025, versus $886000.0 for Q2 2025 and $812000.0 for Q1 2025.